Yayın: Microbiological aspects of Fournier's gangrene
| dc.contributor.buuauthor | Yılmaz, Tuncay | |
| dc.contributor.buuauthor | Gülcü, Barış | |
| dc.contributor.buuauthor | Öztürk, Ersin | |
| dc.contributor.buuauthor | Işık, Özgen | |
| dc.contributor.department | Tıp Fakültesi | |
| dc.contributor.department | Cerrahi Ana Bilim Dalı | |
| dc.contributor.orcid | 0000-0002-9541-5035 | |
| dc.contributor.researcherid | AAW-9602-2020 | |
| dc.contributor.researcherid | P-5779-2019 | |
| dc.contributor.researcherid | ABH-2238-2021 | |
| dc.contributor.scopusid | 6701800362 | |
| dc.contributor.scopusid | 56618783200 | |
| dc.contributor.scopusid | 36600543700 | |
| dc.contributor.scopusid | 35070171400 | |
| dc.date.accessioned | 2022-12-28T06:36:46Z | |
| dc.date.available | 2022-12-28T06:36:46Z | |
| dc.date.issued | 2017-02-23 | |
| dc.description.abstract | Background: Fournier's gangrene (FG) is a devastating disease that is characterized by necrotizing fasciitis of the perineal, genital, or perianal region. Broad-spectrum antibiotics are the key component of its treatment. However, there is paucity of data regarding the optimal empirical antibiotherapy for FG. Materials and methods: Data from patients who underwent surgery for FG between January 2007 and December 2012 were retrieved from a prospectively collected departmental FG database. Demographics, clinical characteristics, causative pathogens and drug susceptibility/resistance were evaluated. Results: Fifty patients with a median age of 58.5 (22-83) years were included. The perianal origin (58%) was most commonly affected. A positive growth was found in specimen cultures of 48 (96%) patients. The median number of bacterial strains that grew in the cultures was 3 (0-10). Amikacin was the antibiotic with the highest frequency of sensitivity (74%), while the highest resistance was observed against ampicillin-sulbactam (64%). Escherichia coli was the most common microorganism (72%). Acinetobacter baumannii and Klebsiella pneumonia were significantly more common in patients who required mechanical ventilation. The mortality rate was 26%. An Uludag Fournier's Gangrene Severity Index (UFGSI) score of >9.5 and ventilatory support requirement were factors associated with an increased rate of mortality. Acinetobacter baumannii was the only microorganism which was associated with an increased mortality rate. Conclusion: Causative pathogens in FG appeared to be shifting; thus, empirical antibiotic treatment for this disease should be modified. We recommend 3rd-generation cephalosporin, metronidazole and amikacin for empirical therapy. | |
| dc.identifier.citation | Yılmazlar, T. vd. (2017). ''Microbiological aspects of Fournier's gangrene''. International Journal of Surgery, 40, 135-138. | |
| dc.identifier.doi | 10.1016/j.ijsu.2017.02.067 | |
| dc.identifier.endpage | 138 | |
| dc.identifier.issn | 1743-9191 | |
| dc.identifier.pubmed | 28257985 | |
| dc.identifier.scopus | 2-s2.0-85014506784 | |
| dc.identifier.startpage | 135 | |
| dc.identifier.uri | https://doi.org/10.1016/j.ijsu.2017.02.067 | |
| dc.identifier.uri | https://www.sciencedirect.com/science/article/pii/S1743919117301929 | |
| dc.identifier.uri | 1743-9159 | |
| dc.identifier.uri | http://hdl.handle.net/11452/30124 | |
| dc.identifier.volume | 40 | |
| dc.identifier.wos | 000402486400022 | |
| dc.indexed.wos | SCIE | |
| dc.language.iso | en | |
| dc.publisher | Elsevier | |
| dc.relation.journal | International Journal of Surgery | |
| dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.subject | Surgery | |
| dc.subject | Empiric antimicrobial therapy | |
| dc.subject | Microbial | |
| dc.subject | Necrotizing fasciitis | |
| dc.subject | Ventilator-associated pneumonia | |
| dc.subject | Predictors | |
| dc.subject | Management | |
| dc.subject | Mortality | |
| dc.subject.emtree | Amikacin | |
| dc.subject.emtree | Cefazolin | |
| dc.subject.emtree | Cefepime | |
| dc.subject.emtree | Cephalosporin | |
| dc.subject.emtree | Ciprofloxacin | |
| dc.subject.emtree | Colistin | |
| dc.subject.emtree | Daptomycin | |
| dc.subject.emtree | Gentamicin | |
| dc.subject.emtree | Imipenem | |
| dc.subject.emtree | Levofloxacin | |
| dc.subject.emtree | Meropenem | |
| dc.subject.emtree | Metronidazole | |
| dc.subject.emtree | Moxifloxacin | |
| dc.subject.emtree | Piperacillin plus tazobactam | |
| dc.subject.emtree | Sultamicillin | |
| dc.subject.emtree | Teicoplanin | |
| dc.subject.emtree | Vancomycin | |
| dc.subject.emtree | Antiinfective agent | |
| dc.subject.emtree | Acinetobacter baumannii | |
| dc.subject.emtree | Adult | |
| dc.subject.emtree | Aged | |
| dc.subject.emtree | Antibiotic resistance | |
| dc.subject.emtree | Antibiotic sensitivity | |
| dc.subject.emtree | Article | |
| dc.subject.emtree | Artificial ventilation | |
| dc.subject.emtree | Bacterial growth | |
| dc.subject.emtree | Bacterium culture | |
| dc.subject.emtree | Burkholderia gladioli | |
| dc.subject.emtree | Citrobacter | |
| dc.subject.emtree | Clinical article | |
| dc.subject.emtree | Corynebacterium | |
| dc.subject.emtree | Disease severity assessment | |
| dc.subject.emtree | Enterococcus | |
| dc.subject.emtree | Escherichia coli | |
| dc.subject.emtree | Fournier gangrene | |
| dc.subject.emtree | Human | |
| dc.subject.emtree | Human tissue | |
| dc.subject.emtree | Klebsiella pneumoniae | |
| dc.subject.emtree | Male | |
| dc.subject.emtree | Methicillin-resistant staphylococcus epidermidis | |
| dc.subject.emtree | Morganella morganii | |
| dc.subject.emtree | Mortality rate | |
| dc.subject.emtree | Nonhuman | |
| dc.subject.emtree | Priority journal | |
| dc.subject.emtree | Pseudomonas aeruginosa | |
| dc.subject.emtree | Serratia | |
| dc.subject.emtree | Staphylococcus aureus | |
| dc.subject.emtree | Streptococcus anginosus | |
| dc.subject.emtree | Fournier gangrene | |
| dc.subject.emtree | Microbial sensitivity test | |
| dc.subject.emtree | Microbiology | |
| dc.subject.emtree | Middle aged | |
| dc.subject.emtree | Prospective study | |
| dc.subject.emtree | Very elderly | |
| dc.subject.emtree | Female | |
| dc.subject.mesh | Adult | |
| dc.subject.mesh | Aged | |
| dc.subject.mesh | Aged, 80 and over | |
| dc.subject.mesh | Anti-bacterial agents | |
| dc.subject.mesh | Female | |
| dc.subject.mesh | Fournier gangrene | |
| dc.subject.mesh | Humans | |
| dc.subject.mesh | Male | |
| dc.subject.mesh | Microbial sensitivity tests | |
| dc.subject.mesh | Middle aged | |
| dc.subject.mesh | Prospective studies | |
| dc.subject.scopus | Fournier Gangrene; Bouteloua; Necrotizing Fasciitis | |
| dc.subject.wos | Surgery | |
| dc.title | Microbiological aspects of Fournier's gangrene | |
| dc.type | Article | |
| dc.wos.quartile | Q2 | |
| dspace.entity.type | Publication | |
| local.contributor.department | Tıp Fakültesi/Cerrahi Ana Bilim Dalı | |
| local.indexed.at | Scopus | |
| local.indexed.at | WOS |
